Definium's LSD drug clears bar in first of two Phase 3 anxiety disorder trials

Phase 3positiveLSDPositive

AI Analysis

Summary

Definium Therapeutics announced positive Phase 3 trial results for its oral LSD candidate in generalized anxiety disorder, marking the first of two planned late-stage studies.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Oral LSD candidate passed Phase 3 trial in generalized anxiety disorder

Importance:7/10

Sentiment:

0.80

Phase 3LSDanxiety disordermental healthclinical trial success

Related Companies

$TRAX

Read the original article

Published by Endpoints News on August 12, 2026 11:00 AM

Read Original